Clinical Trial Update: Perioperative Treatment of Resectable Adenocarcinoma of Esophagogastric Junction by Immunotherapy (Adebrelimab) Combined With Chemotherapy (XELOX): a Prospective, Single-center, Feasibility Study [Phase 2]

View source ↗

Summary

Phase 2 feasibility study evaluating perioperative immunotherapy with adebrelimab combined with XELOX (capecitabine and oxaliplatin) for resectable esophagogast…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophagogastric Junction Adenocarcinoma

Drugs mentioned

• Adebrelimab (adebrelimab)
• Capecitabine (capecitabine)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: Ruijin Hospital | Conditions: Esophagogastric Junction Adenocarcinoma | Phase 2 | Status: RECRUITING